On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. Casper van Eijck, his team at Erasmus, and Ronald Brus, MD, the guiding hand at myTomorrows, for their vision and careful diligence in implementing this important analysis of Ampligen as a single-agent therapy for late-stage pancreatic cancer.”ĪIM stock was up 22.4% as of Tuesday afternoon. These exceptional results from Erasmus exceed even our most optimistic expectations. “We started this program in January 2017. Thomas Equels, Aim ImmunoTech CEO, said the following about the news. Latest AIM ImmunoTech Inc (AIM:ASQ) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more. The company also wants to extend its exclusivity rights to the drug. It’s also seeking to conduct Phase2 and Phase 3 trials in the Netherlands to further confirm the results of the EAP. The EAP found that the survival rate for patients taking the drug 200% higher than historical records.ĭue to the extreme nature of the results from the EAP, Aim ImmunoTech is considering seeking fast-track or even breakthrough status from the U.S. It sought to determine the effectiveness of using AIM’s Ampligen in patients suffering from locally advanced/metastatic pancreatic cancer.Īim ImmunoTechnotes that Ampligen was used in patients that had already received systemic chemotherapy. is an immuno-pharma company headquartered in Ocala, Florida and focused on the research and development of therapeutics to treat. October 26, 2022-The Board of Directors (Board) of AIM ImmunoTech Inc. The EAP took place at the Erasmus University Medical Center in the Netherlands. (NYSE: American AIM) (AIM or the Company) today issued. The Company’s lead product, an investigational new drug called Ampligen ® (rintatolimod) is an immuno-modulator with broad spectrum activity being investigated for globally important cancers, viral diseases and disorders of the immune system.įor more information, please visit and connect with the Company on Twitter, LinkedIn, and Facebook.According to an AIM ImmunoTech news release, the company saw significant results from its EAP. The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19. AIM ImmunoTech (AIM) - P/B ratio P/B ratio as of March 2023 : 0.4506 According to AIM ImmunoTech s latest financial reports the company has a price-to-book ratio of 0.4506. The live webcast will be accessible on the Events and Presentations page of the Investors section of the Company’s website,, and will be archived for 90 days following the live event.ĪIM ImmunoTech Inc. Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference Call. Equels, Chief Executive Officer and Christopher McAleer, PhD, Scientific Officer. The call will be hosted by members of AIM’s leadership team, Thomas K. AIM ImmunoTech management will host its inaugural quarterly conference call and live audio webcast to discuss the operational and financial results on Monday, April 3 rd at 8:30 AM ET. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases - including COVID-19, the disease caused by the SARS-CoV-2 virus - today announced that it will report its financial results for the full year Decemafter market close on Friday, March 31, 2023. Its products include Alferon N Injection and Ampligen. AIM ImmunoTech Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Biotech company researching and developing therapeutics to treat various cancers and immune-deficiency disorders. OCALA, Fla., Ma(GLOBE NEWSWIRE) - AIM ImmunoTech Inc. AIM ImmunoTech 666 followers on LinkedIn.
0 Comments
Leave a Reply. |